A Spanish Consensus on the Use of Safinamide for Parkinson's Disease in Clinical Practice
Pagonabarraga Mora, Javier (Institut d'Investigació Biomèdica Sant Pau)
Arbelo, José Matías (Universidad Fernando Pessoa Canarias. Departamento de Medicina)
Grandas, Francisco (Universidad Complutense de Madrid. Departamento de Medicina)
Luquin, Maria-Rosario (Instituto de Investigación Sanitaria de Navarra)
Martinez-Martin, Pablo (Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas)
Rodríguez-Oroz, Mari Cruz (Centre for Applied Medical Research (CIMA), 31008 Pamplona, Spain)
Valldeoriola, Francesc (Universitat de Barcelona. Departament de Medicina)
Kulisevsky, Jaime (Universitat Autònoma de Barcelona. Departament de Medicina)
Universitat Autònoma de Barcelona

Data:	2020
Resum:	Safinamide is an approved drug for the treatment of motor fluctuations in Parkinson's disease (PD). Scarce data are available on its use in clinical practice. A group of Spanish movement disorders specialists was convened to review the use of safinamide across different clinical scenarios that may guide neurologists in clinical practice. Eight specialists with recognized expertise in PD management elaborated the statements based on available evidence in the literature and on their clinical experience. The RAND/UCLA method was carried, with final conclusions accepted after a 2-round modified Delphi process. Higher level of agreement between panellists was reached for the following statements. Safinamide significantly improves mean daily OFF time without troublesome dyskinesias. Adjunctive treatment with safinamide is associated with motor improvements in patients with mid-to-late PD. The efficacy of safinamide on motor fluctuations is maintained at long-term, with no increase over time in dyskinesias severity. The clinical benefits of safinamide on pain and depression remain unclear. Safinamide presents a similar incidence of adverse events compared with placebo. The efficacy and safety of safinamide shown in the pivotal clinical trials are reproduced in clinical practice, with improvement of parkinsonian symptoms, decrease of daily OFF time, control of dyskinesias at the long term, and good tolerability and safety.
Nota:	Altres ajuts: This study was funded by Zambon S.A.U. Medical writing services were funded by Zambon S.A.U.
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	Safinamide ; Efficacy ; Safety ; Fluctuations ; Dyskinesia ; RAND/UCLA appropriateness method
Publicat a:	Brain sciences, Vol. 10 (march 2020) , ISSN 2076-3425

Erratum: https://ddd.uab.cat/record/252625
DOI: 10.3390/brainsci10030176
PMID: 32197462

17 p, 290.4 KB

El registre apareix a les col·leccions:
Documents de recerca > Documents dels grups de recerca de la UAB > Centres i grups de recerca (producció científica) > Ciències de la salut i biociències > Institut de Recerca Sant Pau
Articles > Articles de recerca
Articles > Articles publicats